EXALENZ BIOSCIENCE (Israel) Financial Diagnostics

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 35px;;'>EXE</div>
The current investor indifference towards the small price fluctuations of EXALENZ BIOSCIENCE could raise concerns from investors as the firm closed today at a share price of 0.0 on very low momentum in volume. The company executives did not add any value to EXALENZ BIOSCIENCE investors in December. However, most investors can still diversify their portfolios with EXALENZ BIOSCIENCE to hedge your portfolio against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 0.0. The very small Stock volatility is a good signal to investors with longer term investment horizons. This diagnostics interface makes it easy to digest most current publicly released information about EXALENZ BIOSCIENCE as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis EXALENZ BIOSCIENCE price relationship with some important fundamental indicators such as market cap and management efficiency. See also Investing Opportunities.


The company recorded loss per share of 0.21. EXALENZ BIOSCIENCE had not issued any dividends in recent years. The entity had 1:100 split on 2014-12-21. Exalenz Bioscience Ltd. develops and markets advanced tools for the diagnosing and managing liver and gastroenterology disorders in Israel. Exalenz Bioscience Ltd. is based in Modiin-Maccabim-Reut, Israel. EXALENZ BIOSCIENCE is traded on Tel Aviv Stock Exchange in Israel. To learn more about EXALENZ BIOSCIENC call the company at 972 8 973 7500 or check out http://www.exalenz.com.


EXALENZ BIOSCIENCE is not yet fully synchronised with the market data
EXALENZ BIOSCIENCE has some characteristics of a very speculative penny stock
EXALENZ BIOSCIENCE has high likelihood to experience some financial distress in the next 2 years
The company reported revenue of 13.25 M. Net Loss for the year was (5.29 M) with profit before overhead, payroll, taxes, and interest of 5.75 M.
EXALENZ BIOSCIENC has accumulated about 2.96 M in cash with (5.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.11.

Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 14.14 B.


The company has Profit Margin (PM) of (39.93) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (33.86) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.34.

Management Efficiency

EXALENZ BIOSCIENCE has return on total asset (ROA) of (25.36) % which means that it has lost $25.36 on every $100 spent on asset. This is way below average.

EXALENZ BIOSCIENCE Technical and Predictive Indicators

Did you try this?

Run Watchlist Optimization Now


Watchlist Optimization

Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
All  Next Launch Module
See also Investing Opportunities. Please also try Equity Search module to search for activelly-traded equities including funds and etfs from over 30 global markets.
Company logos by clearbit